CCRC: A pilot project of virologic, pharmacologic and immunologic correlates of gastrointestinal-associated lymphoid tissue immune reconstitution following raltegravir therapy.

Trial Profile

CCRC: A pilot project of virologic, pharmacologic and immunologic correlates of gastrointestinal-associated lymphoid tissue immune reconstitution following raltegravir therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Raltegravir (Primary) ; Efavirenz; Emtricitabine/tenofovir disoproxil fumarate; Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors
  • Indications HIV infections
  • Focus Pharmacodynamics
  • Acronyms CCRC
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Mar 2011 Results presented at the 18th Conference on Retroviruses and Opportunistic Infections.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top